Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited (HKSE: 2096) is trading at HK$11.83, about ₹145 at today's HKD/INR rate, as of 30 Sep 2026, 2:48 AM ET, up 4.05% today. Indian residents can buy Simcere Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$11.25
Today's high
HK$11.89
52 week low
HK$9.07
52 week high
HK$14.38
2096 opened at HK$11.25, closed previously at HK$11.37, and has traded between HK$9.07 and HK$14.38 over the past 52 weeks.
About
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Key statistics
Avg. volume
6.63M
Market cap
HK$30.38B
P/E Ratio
16.56
Price-to-sales ratio
2.99
Enterprise value
CN¥24.40B
Free cash flow yield
4.30%
Debt-to-equity ratio
0.26
Return on equity
14.28%
ROIC
11.05%
Beta
0.72
Dividend yield
1.75%
Last dividend
HK$0.21
Financial overview
Revenue
CN¥7.73B
Earnings per share
CN¥0.54
Free cash flow
CN¥1.15B
Net profit margin
17.98%
Gross margin
82.86%
EBITDA
CN¥1.72B
Revenue growth
16.52%
Similar securities
This is not an investment recommendation
How to buy Simcere Pharmaceutical from India
Indian residents can buy Simcere Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Simcere Pharmaceutical and place an order
Find Simcere Pharmaceutical by name or by its ticker, 2096, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Simcere Pharmaceutical trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Simcere Pharmaceutical position in HKD and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Simcere Pharmaceutical from India
Trading and taxes when buying Simcere Pharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Simcere Pharmaceutical’s current yield is 1.75%.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Simcere Pharmaceutical stock?
Yes. Simcere Pharmaceutical (2096) has been listed on the Hong Kong Stock Exchange since 2020, in the Medical - Pharmaceuticals industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Simcere Pharmaceutical share cost in rupees?
One Simcere Pharmaceutical share is HK$11.83 — about ₹145 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Simcere Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Simcere Pharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Simcere Pharmaceutical?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Simcere Pharmaceutical shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Simcere Pharmaceutical price. Paasa issues a capital-gains statement for your return.
Does Simcere Pharmaceutical pay a dividend, and how is it taxed in India?
Yes. Simcere Pharmaceutical pays a dividend and the current yield is 1.75%; the last declared dividend was HK$0.21 per share, about ₹2.53. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Simcere Pharmaceutical from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Simcere Pharmaceutical a Hong Kong SAR China company, and does that change how it is taxed?
Simcere Pharmaceutical trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Simcere Pharmaceutical trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Simcere Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Simcere Pharmaceutical holding, its cost and its closing value.
How do I sell Simcere Pharmaceutical and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.